KAW

## PATENT COOPERATION TREATY

From the INTERNATIONAL SEARCHING AUTHORITY				
To: ELIZABETH R. SAMPSON TOWNSEND AND TOWNSEND AND CREW LLP TWO EMBARCADER CENTER, EIGHTH FLOOR SAN FRANCISCO, CA 94111	NOTIFICATION OF TRANSMITTAL OF THE INTERNATIONAL SEARCH REPORT AND THE WRITTEN OPINION OF THE INTERNATIONAL SEARCH REPORT AND THE WRITTEN OPINION OF THE INTERNATIONAL			
019904-002610PC	SEARCHING AUTHORITY, OR THE DECLARATION  (PCT Rule 44.1)  Date of mailing (day/month/year)  15001/1114			
Applicant's or agent's file reference	(day/month/year) 15 0C 1 ∠UU4  FOR FURTHER ACTION See paragraphs 1 and 4 below			
International application No. PCT/US04/03183	International filing date (day/month/year) 04 February 2004 (04.02.2004)			
Applicant CORCEPT THERAPEUTICS, INC.				
The applicant is hereby notified that the international search have been established and are transmitted herewith.	h report and the written opinion of the International Searching Authority			
Filing of amendments and statement under Article 19: The applicant is entitled, if he so wishes, to amend the clai	ms of the international application (see Rule 46):			
	normally two months from the date of transmittal of the international			
Where? Directly to the International Bureau of WIPO, 34 chemin des Colombettes 1211 Geneva 20, Switzerland, Facsimile No.: +41 22 740 14 35				
For more detailed instructions, see the notes on the accompanying sheet.				
2. The applicant is hereby notified that no international search report will be established and that the declaration under Article 17(2)(a) to that effect and the written opinion of the International Searching Authority are transmitted herewith.				
3. With regard to the protest against payment of (an) addition				
,	transmitted to the International Bureau together with the applicant's			
no decision has been made yet on the protest; the appl				
4. Reminders				
Bureau. If the applicant wishes to avoid or postpone publication	the international application will be published by the International and an anotice of withdrawal of the international application, or of the Rules 90bis.1 and 90bis.3, respectively, before the completion of the			
international bureau. The international Bureau will send a copy	the written opinion of the International Searching Authority to the of such comments to all designated Offices unless an international These comments would also be made available to the public but not			
(in some Offices even later); otherwise, the applicant must, within entry into the national phase before those designated Offices.	of some designated Offices, a demand for international preliminary entry into the national phase until 30 months from the priority date in 20 months from the priority date, perform the prescribed acts for			
In respect of other designated Offices, the time limit of 30 months	(or later) will apply even if no demand is filed within 19 months.			
See the Annex to Form PCT/IB/301 and, for details about the app Volume II, National Chapters and the WIPO Internet site.	plicable time limits, Office by Office, see the PCT Applicant's Guide,			
Name and mailing address of the ISA/ US	Authorized officer			
Mail Stop PCT, Attn: ISA/US Commissioner for Patents	Theodore J. Criares Bell-Harrisfur			
P.O. Box 1450 Alexandria, Virginia 22313-1450	Telephone No. (571) 272-1600			
Facsimile No. (703) 305-3230	70.0photic 110. (371) 272-1000			
orm PCT/ISA/220 (January 2004)	(See notes on accompanying sheet)			
•				

Sunch upat reid Actide 19 12/15/04 Tile IDS 1/15/05 DOCKETED ZU Written opinin regrand 12/15/04

DOCKETED 204

## PATENT COOPERATION TREATY

# **PCT**

## INTERNATIONAL SEARCH REPORT

(PCT Article 18 and Rules 43 and 44)

Applicant's or agent's file reference 19904-26-1PC	FOR FURTHER see Form PCT/ISA/220 ACTION as well as, where applicable, item 5 below.	
International application No. PCT/US04/03183	International filing date (day/month/year) 04 February 2004 (04.02.2004)	(Earliest) Priority Date (day/month/year) 04 February 2003 (04.02.2003)
Applicant CORCEPT THERAPEUTICS, INC.		
applicant according to Article 18. A co	n prepared by this International Searching appy is being transmitted to the International of a total of sheets.  d by a copy of each prior art document cite.	Bureau.
a. With regard to the language, the language in which it was filed, to the international furnished to this Author b. With regard to any nucleon	e international search was carried out on the bunless otherwise indicated under this item.  I search was carried out on the basis of a transprity (Rule 23.1(b)).  ide and/or amino acid sequence disclosed in unsearchable (See Box No. II)  ng (See Box No. III)	slation of the international application
4. With regard to the title, the text is approved as subm		
5. With regard to the abstract, the text is approved as submething the text has been established applicant may, within to this Authority.	nitted by the applicant.  d, according to Rule 38.2(b), by this Authority one month from the date of mailing of this int	y as it appears in Box No. IV. The ernational search report, submit comments
as suggested by the	published with the abstract is Figure No applicant.  Authority, because the applicant failed to suggentherity, because this figure better character	gest a figure.

Form PCT/ISA/210 (first sheet) (January 2004)

## INTERNATIONAL SEARCH REPORT

International application No.

PCT/US04/03183

A. CLASSIFICATION OF SUBJECT MATTER IPC(7): A61K 31/56				
US CL : 514/179				
According to International Patent Classification (IPC) or to both i	national classification and IPC			
B. FIELDS SEARCHED				
<del></del>				
Minimum documentation searched (classification system followed by classification symbols) U.S.: 514/179				
Documentation searched other than minimum documentation to the	e extent that such documents are included in the fields searched			
Electronic data base consulted during the international search (name of data base and, where practicable, search terms used) Please See Continuation Sheet				
C. DOCUMENTS CONSIDERED TO BE RELEVANT				
Category * Citation of document, with indication, where a	ppropriate, of the relevant passages Relevant to claim No.			
A US 6,150,349 A (SCHATZBERG et al.) 21 Novem	nber 2000 (21.11.2000), 1-14			
	, , , ,			
	1			
	į			
Further documents are listed in the continuation of Box C.	See patent family annex.			
Special categories of cited documents:	"T" later document published after the international filing date or priority			
-F	date and not in conflict with the application but cited to understand the			
"A" document defining the general state of the art which is not considered to be	principle or theory underlying the invention			
of particular relevance				
#EP andiagonalization or notant published on an after the internal filter dec	"X" document of particular relevance; the claimed invention cannot be			
"E" earlier application or patent published on or after the international filing date	considered novel or cannot be considered to involve an inventive step when the document is taken alone			
"L" document which may throw doubts on priority claim(s) or which is cited to	ARREST AND ADMITTALL IS LARGED STORIC			
establish the publication date of another citation or other special reason (as	"Y" document of particular relevance; the claimed invention cannot be			
specified)	considered to involve an inventive step when the document is			
MOR downward and the second start and the second start and	combined with one or more other such documents, such combination			
"O" document referring to an oral disclosure, use, exhibition or other means	being obvious to a person skilled in the art			
"P" document published prior to the international filing date but later than the	"&" document member of the same patent family			
priority date claimed				
Detect the second secondaries of the house of the house	Date 6 - 11 - Calain at a second			
Date of the actual completion of the international search	Date of mailing of the international search report			
20 5	Authorized officer Theodore Marianes  15 CCT 2004  Authorized officer Theodore Marianes  Authorized officer  Authorized offi			
20 September 2004 (20.09.2004)	TO UVI COUT			
Name and mailing address of the ISA/US	Authorized officer 1			
Mail Stop PCT, Attn: ISA/US	Lavenusell-roams for			
Commissioner for Patents	Theodore J. Criares			
P.O. Box 1450				
Alexandria, Virginia 22313-1450	Telephone No. (571) 272-1600			
Facsimile No. (703) 305-3230				

	INTERNATIONAL SEARCH REPORT	International application No. PCT/US04/03183
Continue	ation of B. FIELDS SEARCHED Item 3:	
STN	rched: postpartum, mifepristone	
1		

Form PCT/ISA/210 (extra sheet) (January 2004)

## PATENT COOPERATION TREATY

From the

INTERNATIONAL SEARCH	ING AUTH	ORITY		
To: ELIZABETH R. SAMPSON TOWNSEND AND TOWNSEND AND CREW LLP TWO EMBARCADER CENTER, EIGTH FLOOR SAN FRANCISCO, CA 94111		PCT  WRITTEN OPINION OF THE INTERNATIONAL SEARCHING AUTHORITY		
			Date of mailing	(PCT Rule 43bis.1)
Amilianata and City				15 OCT 2004
Applicant's or agent's file ref	terence		FOR FURTHER	ACTION
19904-26-1PC			See paragraph 2 below	
International application No.	ļ	International filing date	(day/month/year)	Priority date (day/month/year)
PCT/US04/03183		04 February 2004 (04.0	2.2004)	04 February 2003 (04.02.2003)
International Patent Classifica	ation (IPC) o	or both national classifica	tion and IPC	
IPC(7): A61K 31/56 and US	Cl.: 514/17	9		
Applicant				
CORCEPT THERAPEUTICS	S, INC.			
1. This oninion contains ind	liantiona sala	4		
1. This opinion contains indi		_	18:	
	— — — — — — — — — — — — — — — — — — —			
Box No. II F	o. II Priority			
1 1	Box No. III Non-establishment of opinion with regard to novelty, inventive step and industrial applicability			ntive step and industrial applicability
Box No. IV L	Lack of unity of invention			
Box No. V R	Reasoned statement under Rule 43bis.1(a)(i) with regard to novelty, inventive step or industrial applicability; citations and explanations supporting such statement			
1 1 1	Certain documents cited			
		cts in the international app	olication	
		rvations on the internation		
2. FURTHER ACTION				
If a demand for international preliminary examination is made, this opinion will be considered to be a written opinion of the International Preliminary Examining Authority ("IPEA") except that this does not apply where the applicant chooses an Authority other than this one to be the IPEA and the chosen IPEA has notified the International Bureau under Rule 66.1bis (b) that written opinions of this International Searching Authority will not be so considered.				
If this opinion is, as provided above, considered to be a written opinion of the IPEA, the applicant is invited to submit to the IPEA a written reply together, where appropriate, with amendments, before the expiration of 3 months from the date of mailing of Form PCT/ISA/220 or before the expiration of 22 months from the priority date, whichever expires later.				
For further options, see Fo	orm PCT/IS	A/220.	rour die prior	and, whichever expires later.
3. For further details, see not	tes to Form	PCT/ISA/220.		
Name and mailing address of the			Authorized officer	0.04 //
Mail Stop PCT, Attn: IS Commissioner for Patent	SA/US		Lalerie	1 sell-Harris an
P.O. Box 1450		ĺ	Incodore Jechan	Bell-Harrisfin
Alexandria, Virginia 223 Facsimile No. (703) 305-3230				<sup>(1)</sup> 272-1600
Form PCT/ISA/237 (cover sheet)	) (January 2	004)		

## WRITTEN OPINION OF THE INTERNATIONAL SEARCHING AUTHORITY

International application No.

PCT/US04/03183

Box No. I Basis of this opinion
1. With regard to the language, this opinion has been established on the basis of the international application in the language in whi it was filed, unless otherwise indicated under this item.
This opinion has been established on the basis of a translation from the original language into the following language which is the language of a translation furnished for the purposes of international search (under Rules 12.3 and 23.1(b)).
2. With regard to any nucleotide and/or amino acid sequence disclosed in the international application and necessary to the claimed invention, this opinion has been established on the basis of:
a. type of material
a sequence listing
table(s) related to the sequence listing
b. format of material
in written format
in computer readable form
c. time of filing/furnishing
contained in international application as filed.
filed together with the international application in computer readable form.
furnished subsequently to this Authority for the purposes of search.
In addition, in the case that more than one version or copy of a sequence listing and/or table relating thereto has been filed or furnished, the required statements that the information in the subsequent or additional copies is identical to that in the application as filed or does not go beyond the application as filed, as appropriate, were furnished.  4. Additional comments:
rm PCT/ISA/237(Box No. I) (January 2004)

# WRITTEN OPINION OF THE INTERNATIONAL SEARCHING AUTHORITY

International application No. PCT/US04/03183

Inventive step (IS)  Claims NONE  Claims 1-14  Claims NONE  Industrial applicability (IA)  Claims 1-14  Claims 1-14  Y  Claims 1-14  Y  Claims 1-14  Y  Claims 1-14  Y  Claims 1-14	. Statement			
Inventive step (IS)  Claims NONE  Claims 1-14  Claims NONE  Industrial applicability (IA)  Claims 1-14  Claims NONE  Claims NONE  Claims 1-14  Claims NONE  Citations and explanations:  Industrial applications:  Industrial appl	Novelty (N)	<b>01</b> :		
Inventive step (IS)  Claims 1-14  Claims NONE  Industrial applicability (IA)  Claims 1-14  Claims NONE  Claims NONE  Citations and explanations:  laims 1-14 meet the criteria set out in PCT Article 33(2)-(3), because the prior art does not teach or fairly suggest the use of applicant's claimed known compounds administered to treat postpartum depression.per se.	riovery (14)			Y
Claims NONE  Industrial applicability (IA)  Claims 1-14  Claims NONE  Claims NONE  Citations and explanations:  aims 1-14 meet the criteria set out in PCT Article 33(2)-(3), because the prior art does not teach or fairly suggest the use of plicant's claimed known compounds administered to treat postpartum depression.per se.  aima 1-14 meet the criteria set out in PCT Article 33(4) and thus have industrial conflictabilities to the set of		Claims	NONE	N
Industrial applicability (IA)  Claims 1-14  Claims NONE  Claims NONE  Claims NONE  None  Citations and explanations:  aims 1-14 meet the criteria set out in PCT Article 33(2)-(3), because the prior art does not teach or fairly suggest the use of plicant's claimed known compounds administered to treat postpartum depression.per se.  aima 1-14 meet the criteria set out in PCT Article 33(4) and thus have industrial architecture to the criteria set out in PCT Article 33(4) and thus have industrial architecture to the criteria set out in PCT Article 33(4).	Inventive step (IS)	Claims	1-14	Y
Industrial applicability (IA)  Claims 1-14  Claims NONE  Citations and explanations:  laims 1-14 meet the criteria set out in PCT Article 33(2)-(3), because the prior art does not teach or fairly suggest the use of plicant's claimed known compounds administered to treat postpartum depression.per se.  laima 1-14 meet the criteria set out in PCT Article 33(4) and thus have industrial conflict.		Claims	NONE	N
Claims NONE  Citations and explanations:  aims 1-14 meet the criteria set out in PCT Article 33(2)-(3), because the prior art does not teach or fairly suggest the use of plicant's claimed known compounds administered to treat postpartum depression.per se.  aima 1-14 meet the criteria set out in PCT Article 33(4) and thus have industrial article in the criteria set out in PCT Article 33(4).	Industrial applicability (IA)	CI :		
Citations and explanations:  aims 1-14 meet the criteria set out in PCT Article 33(2)-(3), because the prior art does not teach or fairly suggest the use of plicant's claimed known compounds administered to treat postpartum depression.per se.  aima 1-14 meet the criteria set out in PCT Article 33(4) and thus have industrial conditions to the criteria set out in PCT Article 33(4).	industrial applicatifity (IA)			YI
aims 1-14 meet the criteria set out in PCT Article 33(2)-(3), because the prior art does not teach or fairly suggest the use of plicant's claimed known compounds administered to treat postpartum depression.per se.  aima 1-14 meet the criteria set out in PCT Article 33(4) and thus have industrial conditional conditions.		Claims	NONE	N
aims 1-14 meet the criteria set out in PCT Article 33(2)-(3), because the prior art does not teach or fairly suggest the use of plicant's claimed known compounds administered to treat postpartum depression per se.	Citations and explanations:			

#### NOTES TO FORM PCT/ISA/220 (continued)

The letter must indicate the differences between the claims as filed and the claims as amended. It must, in particular, indicate, in connection with each claim appearing in the international application (it being understood that identical indications concerning several claims may be grouped), whether

- (i) the claim is unchanged;
- (ii) the claim is cancelled;
- (iii) the claim is new;
- (iv) the claim replaces one or more claims as filed;
- (v) the claim is the result of the division of a claim as filed.

## The following examples illustrate the manner in which amendments must be explained in the accompanying letter:

- 1. [Where originally there were 48 claims and after amendment of some claims there are 51]: "Claims 1 to 29, 31, 32, 34, 35, 37 to 48 replaced by amended claims bearing the same numbers; claims 30, 33 and 36 unchanged; new claims 49 to 51 added."
- [Where originally there were 15 claims and after amendment of all claims there are 11]: "Claims 1 to 15 replaced by amended claims 1 to 11."
- [Where originally there were 14 claims and the amendments consist in cancelling some claims and in adding new claims]:
   "Claims 1 to 6 and 14 unchanged; claims 7 to 13 cancelled; new claims 15, 16 and 17 added." or
   "Claims 7 to 13 cancelled; new claims 15, 16 and 17 added; all other claims unchanged."
- 4. [Where various kinds of amendments are made]:
  "Claims 1-10 unchanged; claims 11 to 13, 18 and 19 cancelled; claims 14, 15 and 16 replaced by amended claim 14; claim 17 subdivided into amended claims 15, 16 and 17; new claims 20 and 21 added."

#### "Statement under Article 19(1)" (Rule 46.4)

The amendments may be accompanied by a statement explaining the amendments and indicating any impact that such amendments might have on the description and the drawings (which cannot be amended under Article 19(1)).

The statement will be published with the international application and the amended claims.

### It must be in the language in which the international application is to be published.

It must be brief, not exceeding 500 words if in English or if translated into English.

It should not be confused with and does not replace the letter indicating the differences between the claims as filed and as amended. It must be filed on a separate sheet and must be identified as such by a heading, preferably by using the words "Statement under Article 19(1)."

It may not contain any disparaging comments on the international search report or the relevance of citations contained in that report. Reference to citations, relevant to a given claim, contained in the international search report may be made only in connection with an amendment of that claim.

#### Consequence if a demand for international preliminary examination has already been filed

If, at the time of filing any amendments and any accompanying statement, under Article 19, a demand for international preliminary examination has already been submitted, the applicant must preferably, at the time of filing the amendments (and any statement) with the International Bureau, also file with the International Preliminary Examining Authority a copy of such amendments (and of any statement) and, where required, a translation of such amendments for the procedure before that Authority (see Rules 55.3(a) and 62.2, first sentence). For further information, see the Notes to the demand form (PCT/IPEA/401).

### Consequence with regard to translation of the international application for entry into the national phase

The applicant's attention is drawn to the fact that, upon entry into the national phase, a translation of the claims as amended under Article 19 may have to be furnished to the designated/elected Offices, instead of, or in addition to, the translation of the claims as filed.

For further details on the requirements of each designated/elected Office, see the PCT Applicant's Guide, Volume II.

# This Page is Inserted by IFW Indexing and Scanning Operations and is not part of the Official Record.

## **BEST AVAILABLE IMAGES**

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images include but are not limited to the items checked:
☐ BLACK BORDERS
☐ IMAGE CUT OFF AT TOP, BOTTOM OR SIDES
☐ FADED TEXT OR DRAWING
☐ BLURRED OR ILLEGIBLE TEXT OR DRAWING
☐ SKEWED/SLANTED IMAGES
☐ COLOR OR BLACK AND WHITE PHOTOGRAPHS
☐ GRAY SCALE DOCUMENTS
LINES OR MARKS ON ORIGINAL DOCUMENT
☐ REFERENCE(S) OR EXHIBIT(S) SUBMITTED ARE POOR QUALITY
☐ OTHER:

## IMAGES ARE BEST AVAILABLE COPY.

As rescanning these documents will not correct the image problems checked, please do not report these problems to the IFW Image Problem Mailbox.